101 related articles for article (PubMed ID: 29970572)
1. Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer.
Izuchi D; Fukagawa S; Yotsumoto F; Shigekawa K; Yoshikawa K; Hirakawa T; Kiyoshima C; Ouk NS; Urushiyama D; Katsuda T; Miyata K; Ito T; Kurakazu M; Araki R; Sanui A; Miyahara D; Murata M; Ito H; Shirota K; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2018 Jul; 38(7):4347-4351. PubMed ID: 29970572
[TBL] [Abstract][Full Text] [Related]
2. Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer.
Miyata K; Yotsumoto F; Fukagawa S; Kiyoshima C; Ouk NS; Urushiyama D; Ito T; Katsuda T; Kurakazu M; Araki R; Sanui A; Miyahara D; Murata M; Shirota K; Yagi H; Takono T; Kato K; Yaegashi N; Akazawa K; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3955-3960. PubMed ID: 28668900
[TBL] [Abstract][Full Text] [Related]
3. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
4. Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA.
Hikita S; Yotsumoto F; Fukami T; Horiuchi S; Sanui A; Miyata K; Nam SO; Tsujioka H; Ueda T; Shirota K; Yoshizato T; Maeda K; Ishikawa T; Okuno Y; Kuroki M; Mekada E; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2553-9. PubMed ID: 21873174
[TBL] [Abstract][Full Text] [Related]
5. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
7. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
8. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
10. BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.
Miyamoto S; Yotsumoto F; Ueda T; Fukami T; Sanui A; Miyata K; Nam SO; Fukagawa S; Katsuta T; Maehara M; Kondo H; Miyahara D; Shirota K; Yoshizato T; Kuroki M; Nishikawa H; Saku K; Tsuboi Y; Ishitsuka K; Takamatsu Y; Tamura K; Matsunaga A; Hachisuga T; Nishino S; Odawara T; Maeda K; Manabe S; Ishikawa T; Okuno Y; Ohishi M; Hikita T; Mizushima H; Iwamoto R; Mekada E
BMC Cancer; 2017 Jan; 17(1):89. PubMed ID: 28143428
[TBL] [Abstract][Full Text] [Related]
11. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy.
Lian C; Ruan L; Shang D; Wu Y; Lu Y; Lü P; Yang Y; Wei Y; Dong X; Ren D; Chen K; Liu H; Tu Z
Cancer Biother Radiopharm; 2016 Apr; 31(3):85-90. PubMed ID: 27093342
[TBL] [Abstract][Full Text] [Related]
12. Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.
Shetty P; Patil VS; Mohan R; D'souza LC; Bargale A; Patil BR; Dinesh US; Haridas V; Kulkarni SP
Ann Clin Biochem; 2017 Jul; 54(4):463-471. PubMed ID: 27496793
[TBL] [Abstract][Full Text] [Related]
13. HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of
Yotsumoto F; Fukagawa S; Miyata K; Nam SO; Katsuda T; Miyahara D; Odawara T; Manabe S; Ishikawa T; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3825-3831. PubMed ID: 28668882
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
15. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
Nam SO; Yotsumoto F; Miyata K; Suzaki Y; Yagi H; Odawara T; Manabe S; Ishikawa T; Kuroki M; Mekada E; Miyamoto S
Anticancer Res; 2014 Aug; 34(8):4615-20. PubMed ID: 25075108
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer.
Chung HW; Kong HY; Lim JB
World J Gastroenterol; 2015 Feb; 21(7):2080-8. PubMed ID: 25717241
[TBL] [Abstract][Full Text] [Related]
18. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
Nather A; Mayerhofer K; Grimm C; Hefler L; Leodolter S; Obermair A; Joura EA
Anticancer Res; 2003; 23(3C):2991-4. PubMed ID: 12926151
[TBL] [Abstract][Full Text] [Related]
20. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3143-9. PubMed ID: 20871033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
